Key result
MedInzh-BIO xenopericardial prosthesis is linked to improved quality of life and ~95% one-year survival.
Why the study?
Surgical correction of degenerative aortic valve disease should improve quality of life alongside hemodynamics, but outcomes with the MedInzh-BIO xenopericardial carcass prosthesis needed evaluation.
Does surgical aortic valve replacement with a MedInzh-BIO xenopericardial prosthesis improve quality of life and survival in patients with degenerative aortic stenosis?
Cohort (n=91)
Does surgical aortic valve replacement with a MedInzh-BIO xenopericardial prosthesis improve quality of life and survival in patients with degenerative aortic stenosis?
Implantation of the MedInzh-BIO xenopericardial prosthesis for degenerative aortic stenosis is associated with significant improvements in quality of life and high 1-year survival.
Should not yet change practice in degenerative aortic stenosis; leaves open MedInzh-BIO efficacy versus alternatives in randomized trials.
Aim To evaluate quality of life (QoL), general survival, and development of complications in patents one year after surgical aortic valve (AV) replacement with a MedInzh-BIO xenopericardial carcass prosthesis.Material and methods Degenerative AV disease is one of the most common cardiovascular diseases that gives place only to ischemic heart disease. Surgical correction of the AV defect should be aimed not only at hemodynamic outcomes but also at improvement of QoL. This study included 91 patients (48 women and 43 men), who were implanted with a MedInzh-BIO biological xenopericardial prosthesis in aortic position from January 2017 through March 2020. Mean age of patients was 69.96±4.4 years. QoL was evaluated with a standard SF-36 questionnaire. Also, survival and complications were analyzed one year after surgery.Results Data analysis before and one year after surgery showed a significant improvement of QoL. Postoperative one-year survival was 95.4 %, and major valve-associated complications were absent in 94.5% of cases. During one year, four patients died after 1, 6, 8, and 10 months of follow-up, respectively.Conclusion The improvement of QoL following the AV replacement with a novel xenopericardial carcass prosthesis with the "easy change" system indicates the clinical and functional effectiveness of the used method. The results of the study demonstrated improvements of both the physical health component and the subjective emotional assessment. Postoperative one-year survival was 95.4 %, and major valve-associated complications were absent in 94.5% of cases.
No takes yet. Share an insight, caveat, or question.
Косовских et al. (2023) conducted a cohort in Degenerative aortic valve disease (n=91). MedInzh-BIO xenopericardial carcass prosthesis was evaluated on One-year survival. Implantation of a MedInzh-BIO xenopericardial prosthesis significantly improved quality of life, with a 1-year survival of 95.4% and absence of major complications in 94.5% of patients.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: